Vitamin D or 1,25-dihydroxycholecalciferol (1,25D3) inhibits proliferation, induces differentiation and modulates cell cycle control in a variety of normal and malignant cells. The applicants have demonstrated over the previous funding period that 1,25D3 or its analogs have significant anti-proliferative activity, arrest cells in G0/G1, induce expression of p27 and p21, induce PARP cleavage and enhance the anti-tumor activity of conventional chemotherapeutic agents. Dexamethasone (dex) enhances 1,25D3-mediated anti-proliferative effects and decreases 1,25D3 induced hypercalcemia: these activities may be mediated by effects on the VDr. In addition, they have completed a phase I trial with sc calcitriol in which they determined the MTD and calcitriol pharmacokinetics. The applicants propose to examine effects of 1,25D3 by the following specific aims 1) To examine the anti-tumor activity and the mechanisms involved with 1,25D3 in combination with carboplatin and/or paclitaxel by determining a) the optimum schedule- and time-dependent parameters, b) the role of apoptosis and intracellular Ca2+ changes for these effects, c) the role of cell cycle arrest, and d) the toxicities, MTD and carboplatin pharmacokinetics of calcitriol administered sc for 3 days before and after carboplatin in patients with advance solid tumors; 2) To examine the mechanisms involved in 1,25D3- mediated cell cycle arrest through a) effects on cell cycle check points, b) the role of p21 and p27, and c) the effect of calcitriol on cell cycle status, apoptosis, and VDR expression in prostate cancer patients treated with calcitriol prior to prostatectomy; and 3) To determine the role of glucocorticoids in 1,25D3-mediated activities by a) examining the effect of dex on enhanced anti-proliferative activity, b) on the down-modulation of VDR in the intestinal mucosa, and c) the effect of prednisone in combination with sc calcitriol on toxicity, the MTD and calcitriol pharmacokinetics in patients with advanced tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA067267-05
Application #
2882421
Study Section
Special Emphasis Panel (ZRG2-ET-1 (01))
Program Officer
Xie, Heng
Project Start
1995-05-01
Project End
2003-02-28
Budget Start
1999-03-01
Budget End
2000-02-29
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Long, Mark D; Sucheston-Campbell, Lara E; Campbell, Moray J (2015) Vitamin D receptor and RXR in the post-genomic era. J Cell Physiol 230:758-66
Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71
Mazzilli, Sarah A; Hershberger, Pamela A; Reid, Mary E et al. (2015) Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model. Cancer Prev Res (Phila) 8:895-904
Steck, Susan E; Arab, Lenore; Zhang, Hongmei et al. (2015) Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP. PLoS One 10:e0125151
Ma, Yingyu; Yu, Wei-Dong; Hidalgo, Alejandro A et al. (2013) Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle 12:743-52
Liu, Biao; Morrison, Carl D; Johnson, Candace S et al. (2013) Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget 4:1868-81
Luo, Wei; Hershberger, Pamela A; Trump, Donald L et al. (2013) 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol 136:252-7
Ma, Yingyu; Yu, Wei-Dong; Su, Bing et al. (2013) Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1ýý,25-dihydroxycholecalciferol. Cancer 119:563-74
Luo, Wei; Yu, Wei-Dong; Ma, Yingyu et al. (2013) Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res 73:2289-97
Shen, He; Morrison, Carl D; Zhang, Jianmin et al. (2013) 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget 4:2124-34

Showing the most recent 10 out of 62 publications